These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 34566211)

  • 21. The good toxin: 10 years of experience with botulinum toxin A in the treatment of benign essential blepharospasm.
    Lai KK; Kuk AK; Chan E; Ko ST
    Eur J Ophthalmol; 2021 May; 31(3):1345-1350. PubMed ID: 32544987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm.
    Vivancos-Matellano F; Rodríguez-Sanz A; Herrero-Infante Y; Mascías-Cadavid J
    Neuroophthalmology; 2019 Nov; 43(5):277-283. PubMed ID: 31741669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity Associated with Botulinum Toxin Treatment.
    Bellows S; Jankovic J
    Toxins (Basel); 2019 Aug; 11(9):. PubMed ID: 31454941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia.
    Bladen JC; Feldman I; Favor M; Dizon M; Litwin A; Malhotra R
    Eye (Lond); 2019 Mar; 33(3):349-352. PubMed ID: 30202071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.
    Frampton JE; Silberstein S
    Drugs; 2018 Apr; 78(5):589-600. PubMed ID: 29532439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum toxin: State of the art.
    Jankovic J
    Mov Disord; 2017 Aug; 32(8):1131-1138. PubMed ID: 28639368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AbobotulinumtoxinA: A 25-Year History.
    Monheit GD; Pickett A
    Aesthet Surg J; 2017 May; 37(suppl_1):S4-S11. PubMed ID: 28388718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems.
    Kumar R; Dhaliwal HP; Kukreja RV; Singh BR
    Semin Neurol; 2016 Feb; 36(1):10-9. PubMed ID: 26866491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemifacial spasm: The past, present and future.
    Chaudhry N; Srivastava A; Joshi L
    J Neurol Sci; 2015 Sep; 356(1-2):27-31. PubMed ID: 26111430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Survey of Current Blepharospasm Treatment Patterns Among Oculoplastic Surgeons.
    Broadbent TJ; Wesley RE; Mawn LA
    Ophthalmic Plast Reconstr Surg; 2016; 32(1):24-7. PubMed ID: 25811162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports.
    Torres S; Hamilton M; Sanches E; Starovatova P; Gubanova E; Reshetnikova T
    Clin Cosmet Investig Dermatol; 2014; 7():11-7. PubMed ID: 24379687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffusion of botulinum toxins.
    Brodsky MA; Swope DM; Grimes D
    Tremor Other Hyperkinet Mov (N Y); 2012; 2():. PubMed ID: 23440162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of botulinum toxins.
    Naumann M; Boo LM; Ackerman AH; Gallagher CJ
    J Neural Transm (Vienna); 2013 Feb; 120(2):275-90. PubMed ID: 23008029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical applications of botulinum toxin.
    Dressler D
    Curr Opin Microbiol; 2012 Jun; 15(3):325-36. PubMed ID: 22770659
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical relevance of botulinum toxin immunogenicity.
    Benecke R
    BioDrugs; 2012 Apr; 26(2):e1-9. PubMed ID: 22385408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum Toxin Deaths: What is the Fact?
    Omprakash Hm ; Rajendran Sc
    J Cutan Aesthet Surg; 2008 Jul; 1(2):95-7. PubMed ID: 20300354
    [No Abstract]   [Full Text] [Related]  

  • 38. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going.
    Sahai A; Khan MS; Gregson N; Smith K; Dasgupta P;
    Nat Clin Pract Urol; 2007 Jul; 4(7):379-86. PubMed ID: 17615549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs.
    Löscher W; Schmidt D
    Epilepsia; 2006 Aug; 47(8):1253-84. PubMed ID: 16922870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.